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Abstract
Background: Chondrogenic mesenchymal stem cells (MSCs) have not yet been used to address the clinical demands
of large osteochondral joint surface defects. In this study, self-assembling tissue intermediates (TIs) derived from human
periosteum-derived stem/progenitor cells (hPDCs) were generated and validated for stable cartilage formation in vivo
using two different animal models.
Methods: hPDCs were aggregated and cultured in the presence of a novel growth factor (GF) cocktail comprising of
transforming growth factor (TGF)-β1, bone morphogenetic protein (BMP)2, growth differentiation factor (GDF)5, BMP6,
and fibroblast growth factor (FGF)2. Quantitative polymerase chain reaction (PCR) and immunohistochemistry were used
to study in vitro differentiation. Aggregates were then implanted ectopically in nude mice and orthotopically in critical-
size osteochondral defects in nude rats and evaluated by microcomputed tomography (µCT) and immunohistochemistry.
Results: Gene expression analysis after 28 days of in vitro culture revealed the expression of early and late chondrogenic
markers and a significant upregulation of NOGGIN as compared to human articular chondrocytes (hACs). Histological
examination revealed a bilayered structure comprising of chondrocytes at different stages of maturity. Ectopically, TIs
generated both bone and mineralized cartilage at 8 weeks after implantation. Osteochondral defects treated with TIs
displayed glycosaminoglycan (GAG) production, type-II collagen, and lubricin expression. Immunostaining for human
nuclei protein suggested that hPDCs contributed to both subchondral bone and articular cartilage repair.
Conclusion: Our data indicate that in vitro derived osteochondral-like tissues can be generated from hPDCs, which are
capable of producing bone and cartilage ectopically and behave orthotopically as osteochondral units.
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Background
Osteochondral and joint surface defects account for up
to 60% of total knee arthroscopies performed in the
United States [1, 2]. Besides pain and functional impair-
ment, localized joint defects are a clear risk factor for
the development of osteoarthritis (OA) when left un-
treated [3–5]. In the United States, 9% of the total popu-
lation older than 30 years suffers from OA of the hip or
knee, where approximately 12% of cases arise secondary
to joint trauma [6]. The poor regenerative capacity of ar-
ticular cartilage and a rather limited understanding of
articular cartilage neogenesis have hampered the deve-
lopment of successful therapies to restore joint surface
defects. Bone marrow stimulation techniques, such as
microfracture, have been widely applied in cases of
chondral and osteochondral injury. However, long-term
results indicate that the reparative tissues consist mostly
of fibrocartilage, resulting in eventual cartilage degener-
ation and thus reintervention [7]. Fresh osteochondral
grafts have provided positive outcomes when applied to
large osteochondral defects, but a shortage of appropri-
ate tissue is a clear limitation towards general clinical
application [8]. Also, decellularized osteochondral allo-
grafts display high failure rates in the treatment of large
osteochondral defects [9]. Therefore, numerous cell-
based therapies have been attempted to address these
limitations. The clinical use of cell-based therapies for
cartilage repair rely on autologous chondrocytes that are
harvested from a low load-bearing area of the patient’s
own knee and transplanted into the defect area (autolo-
gous chondrocyte implantation (ACI)), with or without
the use of supportive scaffolds [10]. Indeed, standard
ACI is relatively successful in isolated deep cartilage de-
fects in otherwise healthy/young joints, but it is not ap-
propriate for osteochondral defects [11]. Mesenchymal
stem cell (MSC)-based therapies have also been
attempted; however, clinical trials report a general ineffi-
cacy when considering functional recovery of damaged
joint surfaces [12–14]. Indeed, to date, only a few studies
have claimed in vitro differentiation of MSCs towards
the stable, articular cartilage phenotype [15–18].
The bone periosteum has long since been investigated
for cartilage and joint surface repair. Originally, the ACI
procedure involved the bone periosteum as a protective,
biologically active membrane that had positive paracrine
effects on implanted chondrocytes [19]. Due to the
abundance of skeletal progenitor cells in the periosteum,
periosteal graft transplantations were also investigated
for osteochondral defect repair. However, despite quali-
tative positive outcomes, data were inconsistent [20, 21].
Considering the joint’s architecture, particularly the
complex interface between cartilage and subchondral
bone, it remains a challenge to generate cell-based con-
structs that not only allow for cartilage and bone
formation, but also possess enough plasticity to operate
a regenerative process orchestrated by the different mi-
croenvironments present in the joint. As recently
reviewed [22], more mature cartilage constructs display
attractive properties for the treatment of cartilage de-
fects due to their increased resistance to proinflamma-
tory cytokines and their capacity to recruit or commit
neighboring cells to the regenerative process. These
properties are provided by their cartilaginous extracellu-
lar matrix (ECM) and may represent a significant advan-
tage to the microfracture and ACI techniques.
Considering the presence of osteo- and chondropro-
genitor cells in the periosteum, it was hypothesized that
human periosteum-derived progenitor cells (hPDCs)
could generate tissue intermediates (TIs) which, upon
implantation in proper environment, would allow the
formation of a stable layer of cartilage and a deep layer
of new endochondral bone. Herein, we show the self-
assembling and osteochondral potential of hPDCs
cultured in vitro for 4 weeks using a novel growth
factor (GF) cocktail [23]. When implanted ectopically
in nude mice, TIs were able to generate multiple
tissues, including mineralized cartilage, bone, and bone
marrow. When implanted into osteochondral defects in
rats we found an intrinsic osteochondral regenerative
potential, suggesting the clinical relevance of this
protocol for joint surface repair.
Methods
Periosteal cell isolation and culture
hPDCs were isolated from periosteal biopsies of dif-
ferent donors undergoing distraction osteogenesis sur-
geries (n = 4; two male and two female donors, aged
28.7 ± 12.3 (mean ± SD) years old) as previously
described [24]. Briefly, the periosteum was stripped
from the tibia, minced, and digested overnight at 37 °C in
type IV collagenase (440 units/mg; Invitrogen, Merelbeke,
Belgium) in growth medium (high-glucose Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Merelbeke,
Belgium) supplemented with 10% fetal bovine serum
(FBS; BioWhittaker, Verviers, Belgium), and an antibiotic–
antimycotic solution (100 units/ml penicillin, 100 μg/ml
streptomycin, and 0.25 μg/ml amphotericin B; Invitro-
gen, Merelbeke, Belgium). A pool of hPDCs was then
created based on identical growth kinetics in vitro and
in vivo bone forming capacity. The ethical committee
for Human Medical Research (KU Leuven) approved all
procedures, and patient informed consent forms were
obtained.
Cell culture and chondrocyte differentiation
Cultures of hPDCs were prepared as previously de-
scribed [25]. Briefly, 20-μl droplets of a cell suspension
containing 20 × 106 cells/ml were seeded in 24-well
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plates and incubated at 37 °C in 95% humidity for 3 h.
These micromasses were allowed to deposit ECM and
to develop cell-to-cell, cell-to-matrix, and cell-to-plastic
interactions in a three-dimensional environment for the
course of 28 days. To induce chondrocyte differenti-
ation, cells were cultured with 500 μl of chemically
defined chondrogenic medium [26] consisting of LG-
DMEM (Gibco, UK) supplemented with 100 μM
ascorbate-2-phosphate, 100 nM dexamethasone, 40 μg/
ml proline, and insulin-transferrin-selenium (ITS) +
premix universal culture supplement (BD Biosciences,
Bedford, MA), including 6.25 mg/ml insulin, 6.25 mg/
ml transferrin, 6.25 mg/ml selenious acid, 1.25 mg/ml
bovine serum albumin (BSA), and 5.35 mg/ml linoleic
acid. This basal chondrogenic medium (BCM) was supple-
mented with 10 ng/ml transforming growth factor (TGF)-
β1, 100 ng/ml bone morphogenetic protein (BMP)2, 100
ng/ml growth differentiation factor (GDF)5, 0.2 ng/ml
fibroblast growth factor (FGF)2, and 1 ng/ml BMP6, as
described elsewhere [23]. Rho kinase inhibitor Y27632
[27] (20 μM) was used to minimize cytoskeletal tension
and prevent cell detachment and the formation of a nec-
rotic center. This medium is referred as “GF cocktail”.
Culture medium was refreshed every 2 days. Negative
control aggregates (CTRL) were cultured in BCM with no
supplementation of GFs. For osteochondral defect im-
plantation, positive control aggregates of hPDCs were cul-
tured in BCM supplemented with 20 μM Rho kinase
inhibitor Y27632 and 10 ng/ml of TGF-β1 for 28 days
(TGF-β1 aggregates).
Healthy human articular chondrocytes were obtained
from patients undergoing hip replacement for osteopor-
otic or malignancy-associated fractures. Briefly, the car-
tilage was sliced into pieces of 4 × 4 mm before being
washed three times in 1% (vol/vol) antibiotic–antimyco-
tic/phosphate-buffered saline (PBS) and incubated with
1 mg/ml pronase (Roche)/DMEM-F12 at 37 °C for 30
min at slow rotation (100 rpm). After overnight incuba-
tion with 1 mg/ml collagenase B (Roche)/DMEM-F12 at
37 °C, chondrocytes were filtered through a 70-μm cell
strainer (Corning), washed twice with PBS, seeded at 1 ×
106 cells/T75 flask and cultured for 7–14 days in main-
tenance medium (DMEM-F12, containing 1% (vol/vol)
antibiotic–antimycotic (Gibco), 10% FBS (Gibco), and 5%
L-glutamine (Thermo scientific)). Passage 2 cells were
used for experiments. The University Hospitals Leuven
Ethics Committee and Biobank Committee approved the
study, and specimens were taken with patients’ informed
consent.
In vivo ectopic and orthotopic bone and cartilage
formation assays
To study ectopic bone and cartilage forming capacity, TIs
were cultured in chondrogenic medium supplemented
with 10 ng/ml TGF-β1, 100 ng/ml BMP2, 100 ng/ml
GDF5, 0.2 ng/ml FGF2, and 1 ng/ml BMP6 for 28 days,
and transplanted subcutaneously into nude mice following
an adapted version of a previously described protocol [28].
Briefly, TIs were gently lifted using a plastic cell scraper
before being washed twice in PBS at room temperature
and then being transplanted onto the subcutaneous tissue
of nude mice (n = 8; 11 weeks, male, NMRInu/nu). Mice
were sacrificed 2, 4, and 8 weeks after implantation and
the explants were immediately incubated in 4% parafor-
maldehyde (PFA) for 1 h at room temperature before be-
ing washed in sterile PBS and preserved at 4 °C.
For orthotopic implantation, TIs were transplanted in
critical-size osteochondral defects (1.4 mm diameter × 1
mm depth) of athymic nude rats (n = 9; 11 weeks; male;
Foxn1nu). One cylindrical osteochondral defect was cre-
ated 2 mm from the top of the intercondylar notch on
the femoral trochlear groove in the knee of each rat.
After wound closure, the rats were allowed to walk freely
in the cage before being sacrificed at 8 weeks. Three ex-
perimental conditions were tested in this model: 1)
critical-size osteochondral defects treated with TIs; 2)
critical-size osteochondral defects treated with TGF-β1
aggregates (see above); (3) critical-size osteochondral de-
fects that received no treatment and are referred to as
“empty defect”.
All animal experimental procedures were approved by
the local ethical committee for animal research (KULeu-
ven). The animals were housed according to the guide-
lines provided by the Animalium Leuven (KULeuven).
Histochemical and immunohistochemical characterization
Ectopic explants and in vitro cultured TIs were fixed for
1 h in 4% PFA before being paraffin embedded and sec-
tioned (5 μm) for histochemical characterization. The
osteochondral defects were fixed overnight in 4% PFA.
For alcian blue staining, samples were deparaffinized
and rehydrated in methanol before being incubated with
1% alcian blue solution (pH 1) for 1 h and the nuclei
counterstained with Nuclear Fast Red for 10 min
followed by dehydration in graded ethanol and mount-
ing. For hematoxylin and eosin (H&E) staining, samples
were deparaffinized as described above and immersed in
Mayer’s hematoxylin solution for 5 min before being
washed for 5 min in tap water and incubated for 7 min
in eosin solution. Samples were then dehydrated in
graded ethanol and mounted.
Immunohistochemistry was performed using rabbi-
t:anti-human antibodies against COL2A1 (1:200; Milli-
pore, Germany), Col1A1 (1:200; ThermoScientific, USA),
and Prg4 (1:300; Abcam, UK), guinea pig:anti-human spe-
cific against osteocalcin (1:200; kindly provided by Prof.
Jeroen Aerssens, KULeuven, Belgium) and mouse:anti-
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human nuclei (1:100; Millipore, Germany). Histological
sections were dewaxed, rehydrated, and subjected to an
antigen retrieval step (Additional file 1: Table S1). En-
dogenous peroxidase activity was quenched with 3%
H2O2 (15 min). Nonspecific binding was blocked using
5% BSA (Sigma, USA) in Tris-buffered saline and 0.1%
Tween 20 (TBST; Sigma, USA) for 30 min. Antibodies
were diluted in TBST (2.5% BSA) and incubated over-
night at 4 °C. Sections were then washed in TBST and
incubated for 40 min with TBST (5% BSA). Samples
were subsequently incubated with horseradish peroxid-
ase (HRP)-conjugated anti-rabbit, anti-mouse, and anti-
guinea pig secondary antibodies (Jackson Laboratory,
USA; 1:500) in TBST (2.5% BSA) for 30 min at room
temperature. After washing, sections were incubated
with DAB+ substrate (Dako, USA) for detection of HRP
enzymatic activity. Nuclei were counterstained with
Mayer’s hematoxylin followed by sample dehydration in
graded ethanol and mounting. Samples were analyzed
using the Leica DMR microscope (Leica, Germany) and
images were acquired and analyzed with Spot Software
V5.1 (SPOT Imaging Solutions, USA).
Bone and mineralized tissue quantification and analysis
Explanted TIs were scanned at a pixel size of 2 μm using
a Phoenix NanoTom S (GE Measurement and Control
Solutions) equipped with a diamond target operated at a
voltage of 70 kV and a current of 100 mA. A 0.5-mm
aluminum filter was used to reduce beam hardening. Re-
construction was performed using the Datos X software
and quantification of mineralized tissue using the CTAn
software (both from Bruker-μCT, Belgium). CTVox
(Bruker-μCT, Belgium) was used for three-dimensional
visualization. Explanted knees were scanned at a pixel
size of 4 μm using the system and settings described
above, with an adjusted current value of 120 mA. After
reconstruction, a cylindrical region of interest (ROI) of
1.5 mm in diameter and 1 mm length within the regen-
erating site was analyzed using the CTAn software (both
from Bruker-μCT, Belgium). Three contralateral nonin-
jured knees were also scanned and used as positive con-
trols for bone quantification and characterization within
the ROI. The bone volume fraction was estimated by
bone volume per tissue volume (BV/TV), the trabecular
structures evaluated by trabecular thickness (Tb.Th), the
average separation of the trabeculae by trabecular separ-
ation (Tb.Sp), and the average number of trabeculae by
trabecular number (Tb.N). The statistical analysis was
performed using one-way analysis of variance (ANOVA),
and statistically significant differences between groups
were further investigated using Tukey’s multiple com-
parison test. Results were considered statistically differ-
ent for P values lower than 0.05.
Total RNA extraction and quantitative reverse transcription
polymerase chain reaction (qRT-PCR) analysis
Total RNA from each construct was isolated using Qia-
gen RNeasy extraction kit (Qiagen, Germany) and
quantified using Nanodrop ND-1000 spectrophotom-
eter (Thermo Scientific). Isolation of total RNA, synthe-
sizing complementary DNA, and running qPCR were
performed as described previously [23]. Each sample
was tested in duplicate and compared with the house-
keeping gene hypoxanthine guanine phosphoribosyl-
transferase (HPRT1), thus allowing normalization of
results. Relative differences in expression were calcu-
lated using the 2 − ΔCT method. The statistical analysis
was performed using Kruskal-Wallis test. Statistically
significant differences between groups were further in-
vestigated using Dunn’s multiple comparison test. Re-
sults were considered statistically different for P values
lower than 0.05.
Results
hPDCs differentiate into the chondrogenic lineage and
generate bilayered tissue intermediates in vitro
To define the stage of differentiation after in vitro cul-
ture, the relative expression of chondrogenic genes was
compared between conditions (Fig. 1a). After 28 days,
SOX9 and COL2A1 mRNA levels were higher in TIs
compared with control aggregates (CTRL); however, ex-
pression of both genes was lower when compared with
human articular chondrocytes (hACs). The expression of
the hypertrophic genes MEF2C and COL10A1 was sig-
nificantly upregulated in TIs when compared with
CTRL; however, only MEF2C displayed a significant in-
crease in TIs when compared with hACs. The expres-
sion of Prg4, whose protein (lubricin) is essential for
proper joint lubrication and function, was expressed in
hACs and CTRL (with no significant difference) but was
significantly downregulated in TIs. The BMP antagonist
NOGGIN was equally expressed between hACs and
CTRL, but significantly upregulated in TIs. Gremlin1,
also a BMP antagonist, was significantly downregulated
in both TIs and CTRL compared with hACs. The ex-
pression of type 1 collagen was similar between TIs and
hACs, suggesting dedifferentiation of the hACs, but sig-
nificantly lower in CTRL when compared with hACs.
Immunohistochemical characterization of TIs was per-
formed to investigate the spatiotemporal expression of
glycosaminoglycans (GAGs), type-II collagen, type-I col-
lagen, and Indian Hedgehog (IHH) (Fig. 1b). A bilayered
construct comprising of at least two phenotypically dif-
ferent cell populations was identified after 14 days in
culture, evolving to a more evident layered construct by
day 28. Alcian blue staining and immunohistochemistry
for type-II collagen revealed deposition of both GAGs
and collagen at day 14 and day 28; however, type-II
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collagen deposition and the typical chondrocyte morph-
ology were restricted to the top cell layers of the con-
struct at day 28 (approximately 262 μm ± 55) (top layers
in Fig. 1b indicated by *). Type-I collagen deposition was
identified at the bottom layers by day 14 (bottom layer
in Fig. 1b indicated by **) but had spread throughout the
constructs by day 28. IHH-positive cells were heteroge-
neously distributed at day 14; however, these were re-
stricted to the top layers by day 28, confirming the
existence of a preferred location for chondrocyte differen-
tiation. Histological results and gene expression analysis
were consistent among two independent experiments.
Overall, these data revealed the potential self-
assembling capacity of hPDCs and their different
chondrogenic commitment across the construct when
cultured in this novel GF cocktail, thus allowing the
formation of multiphased tissue intermediates.
Bone and stable mineralized cartilage are formed after
ectopic implantation
After 28 days of differentiation, TIs were implanted into
the dorsal region of nude mice to study their
osteoinductive and chondroinductive properties in vivo.
Microcomputed tomography (μCT) analysis revealed
mineralization of the ECM as early as 2 weeks posti-
mplantation (Fig. 2). Alcian blue and H&E staining
performed on the explants at 2 and 4 weeks postim-
plantation confirmed their chondrogenic phenotype.
H&E staining performed at 8 weeks postimplantation
revealed that TIs could either form bone ossicles (2/6),
displaying bone, cartilage, and bone marrow cavities, or
remain as stable mineralized cartilage tissue (4/6) dis-
playing either low or no bone-forming capacity. Alcian
blue staining confirmed the presence of only a few rem-
nants of cartilage in the explanted ossicles. Conversely,
mineralized cartilage expressed and deposited GAGs in
its ECM. Mineralization in vivo appears to occur pri-
marily in the Col2- and IHH-positive areas of the con-
struct, as defined by correlation of the 2-week histology
and μCT data (Additional file 2: Figure S1). At later
time points, it is possible that IHH/Col2-negative re-
gions may also mineralize, but this is difficult to assess
due to the continuous contribution of the host cells to
new tissue formation.
Fig. 1 Characterization of TIs at the gene expression and histological levels. a mRNA quantification by qPCR of chondrogenic genes in tissue
intermediates (TIs), control aggregates (CTRL, no GFs) and human articular chondrocytes (hACs). b Longitudinal histological sections (5 μm) of TIs
stained for glycosaminoglycans (alcian blue), type-II collagen, type-I collagen, and Indian Hedgehog (IHH) at 14 and 28 days after in vitro culture.
Top and bottom layers of TIs are identified by * and **, respectively. Dashed lines represent a critical depth at which cells no longer express type-II
collagen or IHH, from top to bottom. Results are representative of two independent experiments. Each experiment was performed using 2–3
technical replicates. In a, error bars are max/min; *P < 0.05, **P < 0.01, ***P < 0.001
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The chondrogenic and osteogenic nature of the ex-
plants was further confirmed by immunohistochemis-
try. Type-I collagen was deposited throughout the
constructs at 2 and 4 weeks postimplantation. In con-
trast, type-II collagen deposition seemed restricted to
the presumed top layers of the TIs, possibly as prede-
fined by the in vitro differentiation step. At 8 weeks,
type-II collagen deposition was either maintained (min-
eralized cartilage) or greatly decreased and replaced by
type-I collagen (ossicles), suggesting cartilage remodel-
ing and endochondral ossification (Fig. 3). Human
osteocalcin-positive cells were found in both ossicles
and mineralized cartilage, suggesting that implanted
hPDCs partially contributed to de novo tissue forma-
tion. This variation could potentially be explained by a
combination of factors, such as the variation between
animals and a certain heterogeneity within the con-
structs after in vitro culture.
Osteochondral regenerative potential of TIs
demonstrated in critical size osteochondral defects
A translational model of osteochondral defect repair was
used to test the functional properties of these TIs.
Critical-size osteochondral defects (1.4 mm diameter × 1
mm depth) were created in the knees of nude rats and
treated with TIs and TGF-β1 aggregates (cultured in
BCM supplemented with 10 ng/ml TGF-β1 for 4 weeks).
Empty defects served as the negative control. For sub-
chondral bone characterization, a region of interest
(ROI) of 1.5 mm diameter × 1 mm depth was drawn at
the site of the defect and compared to a similar area in
contralateral noninjured knees. At 8 weeks postinjury,
macroscopic observation showed integration of the im-
planted constructs at the defect site, which morphologic-
ally resembled the empty defects (Fig. 4). μCT three-
dimensional rendering showed the location of the defect
and suggested a different range of subchondral bone
Fig. 2 Histological and microcomputed tomography (μCT) analysis of in vitro cultured and ectopically implanted TIs. μCT 3D rendering and cross-
sections at the central zone of TIs at 2, 4, and 8 weeks showed extracellular matrix mineralization upon implantation. Histological analysis by alcian
blue and hematoxylin and eosin (H&E) staining showed maintenance of fibrocartilage (FC) and chondrocyte-like cells (C) embedded in a GAG-
positive matrix at 2 and 4 weeks after implantation. At 8 weeks after implantation, different tissues were formed, namely ossicle-like structures (2/6)
and mineralized cartilage showing either low or no bone and bone marrow formation. Results are representative of two independent experiments,
each experiment was performed in triplicate
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Fig. 3 Immunohistological analysis of type-I and type-II collagen deposition and contribution of human (h) cells to bone and cartilage formation
by TIs. Immunohistochemistry showed co-deposition of type-II (Col2) and type-I (Col1) collagens at 2 and 4 weeks after implantation. At 8 weeks
after implantation, ossicle-like structures showed reminiscences of type-II collagen deposition and contribution of human osteocalcin-positive cells
to new bone tissue formation. Mineralized cartilage maintained a dual expression of type-I and type-II collagens and showed positive osteocalcin
immunostaining. Results are representative of two independent experiments, each experiment was performed in triplicate
Fig. 4 Macroscopic view, μCT 3D rendering, and bone quantification and characterization of treated and nontreated osteochondral defects at 8
weeks postinjury. Critical-size osteochondral defects (1 mm depth × 1.4 mm diameter) were treated with tissue intermediates (TIs) or transforming
growth factor (TGF)-β1 aggregates (Agg). Empty osteochondral defects were used as negative controls. Macroscopic view of the osteochondral
defects showed integration of the implanted constructs at the defect site and similar morphology of those receiving no treatment (empty defects).
μCT 3D rendering showed subchondral bone regeneration at the osteochondral defect site. Quantification and characterization of new subchondral
bone formation at the defect site was performed by analyzing a region of interest 1.5 mm diameter × 1 mm depth. n = 3 animals per condition.
One-way ANOVA followed by Tukey’s multiple comparison test was used to analyze the results. *P < 0.05, **P < 0.01, ***P < 0.001
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regeneration between conditions (Fig. 4). Morphological
analysis of the subchondral bone within the regenerating
area showed that defects treated with TIs and empty
defects displayed similar subchondral bone volume (BV/
TV) and bone morphology (P > 0.05) (Fig. 4). Con-
versely, defects treated with TGF-β1 aggregates revealed
limited subchondral bone forming capacity, as the BV/
TV was significantly lower when compared to normal
knees (P < 0.05). The increased BV/TV in defects treated
with TIs and empty defects seemed to occur due to the
appearance of thicker new trabecular bone, as showed
by a significant increase of the trabecular thickness
(Tb.Th) in these two conditions (P < 0.05). Analysis of
trabecular separation (Tb.Sp) indicated that the new
subchondral bone in defects treated with TIs and empty
defects was similar to that of normal knees (P > 0.05),
while defects treated with TGF-β1 aggregates showed
significantly higher Tb.Sp (P < 0.01). The trabecular
number was similar to those in all the experimental con-
ditions, but significantly lower than that of normal knees
(P < 0.001) (Fig. 4). Histological characterization showed
heterogeneous osteochondral regeneration across the de-
fects. Defects treated with TIs showed subchondral bone
regeneration and newly formed cartilage at the joint sur-
face at 8 weeks postinjury (Fig. 5a). In the average re-
sponse, the newly formed cartilage tissue resembled
immature cartilage as shown by alcian blue staining and
polygonal chondrocyte-like cells. However, the best
histological results suggested that TIs can contribute to
fully regenerate the osteochondral unit. Conversely, de-
fects treated with TGF-β1 aggregates displayed an accu-
mulation of nonmineralized fibrocartilage at the putative
location of the subchondral bone and articular cartilage
(Fig. 6b), which may explain the delay/suppression of
the subchondral bone regeneration observed in empty
defects. The histological result with the highest level of
Fig. 5 Histological analysis of osteochondral defects and human cell identification at 8 weeks postinjury. a Alcian blue staining showed articular-
like tissue expressing GAGs in osteochondral defects treated with tissue intermediates (TIs), limited bone forming capacity at the subchondral
level, and the presence of nonfunctional fibrotic tissue in osteochondral defects treated with transforming growth factor (TGF)-β1 aggregates
(Agg), and limited capacity of empty defects to repair articular cartilage. The average and best histological sections are shown. b Immunohisto-
chemistry for human (h)nuclei in defects treated with TIs and TGF-β1 aggregates showed the contribution of human cells (arrow heads) for both
articular and subchondral bone regeneration
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repair for this condition showed sporadic subchondral
bone regeneration, but the articular surface is fibrocarti-
lage. To investigate the contribution of hPDCs to the
newly formed tissues, human cells were tracked using an
anti-human nuclei antibody. The results confirmed that
hPDCs contributed to both articular cartilage and bone
formation in defects treated with TIs, and to a lesser ex-
tent in the TGF-β1 condition (Fig. 5b).
TGF-β1 induces in vitro fibrocartilage formation and
suppresses bone forming capacity of hPDCs in
osteochondral defects
To elucidate the mechanisms by which TIs facilitate bone
and cartilage regeneration as compared with TGF-β1
aggregates, the expression of fibrosis-related genes be-
tween these two conditions was analyzed prior to implant-
ation. Four fibrosis-related gene markers were analyzed by
qRT-PCR, including Col1A1 [29], procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 2b (Plod2b) [30], Tenascin C
(TNC) [31], and Col5A1 [32]. Additionally, SOX9 and
RUNX2, as well as COL2A1 and COL10A1, were analyzed
to assess chondrocyte differentiation and maturation be-
tween conditions (Additional file 3: Figure S2). Gene ex-
pression analysis indicated that PLOD2, COL5A1, and
COL1A1 had a trend for increased expression in TGF-β1
aggregates when compared with TIs, whereas COL1A1
and COL5A1were significantly upregulated in TGF-β1 ag-
gregates (P < 0.01) (Fig. 6a). TNC gene expression did not
Fig. 6 Characterization of tissue intermediates (TIs) or transforming growth factor (TGF)-β1 aggregates (Agg) at the gene expression level before
implantation and histological analysis of type-I collagen (Col1), type-II collagen (Col2), and lubricin deposition at 8 weeks postinjury. a Gene expression
analysis of fibrosis-related genes between conditions. b Immunohistochemistry showed homogeneous deposition of type-I collagen in osteochondral
defects treated with TGF-β1 aggregates, as compared to empty defects and defects treated with TIs. Type-II collagen deposition is present in the pericellular
space of cells in treated defects, but absent at the articular surface of empty defects. Immunohistochemistry for lubricin showed positive staining in treated
osteochondral defects, but negative staining in empty defects. Histology performed in samples representing the average response. For gene expression, the
results are representative of two independent experiments, each experiment was performed in triplicate; error bars are max/min. *P < 0.05, **P < 0.01,
***P < 0.001. CTRL control, hACs human articular chondrocytes, PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2, TNC tenascin C
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change between conditions. Maintenance of a fibrotic
phenotype after orthotopic implantation was confirmed
by immunohistochemistry for type-I collagen in defects
treated with TGF-β1 aggregates. In contrast, defects
treated with TIs and empty defects displayed limited type-
I collagen deposition (Fig. 6b). To further study the func-
tionality of the newly formed tissues between conditions,
immunohistochemistry for type-II collagen and lubricin
was performed. Both proteins were found in treated de-
fects; however, TGF-β1 conditions displayed a fibroblast-
like shape across their volume. In both cases, type-II colla-
gen deposition was found at a lower extent when com-
pared with native surrounding cartilage. In opposition,
empty defects were void of type-II collagen deposition and
lubricin expression.
Discussion
The repair of osteochondral joint surface defects
through MSC-based tissue engineering remains challen-
ging. Previous studies have convincingly shown the posi-
tive effect of TGF-β (TGF-β1 and TGF-β3 specifically)
on chondrocyte differentiation of multiple MSC types,
including hPDCs [25, 33]. However, a single application
of TGF-β proved insufficient to generate cartilage grafts
with similar mechanical and biochemical properties to
native articular cartilage [34, 35], and rather generated
fibrocartilage [36]. In addition, only a few studies have
attempted to repair osteochondral defects using three-
dimensional MSC-based grafts in a scaffold-free experi-
mental setting [37, 38].
In this work, it was hypothesized that TIs generated
from hPDCs cultured in a novel developmentally in-
spired combination of GFs could respond to the stimuli
of the surrounding microenvironment to generate syn-
chronized tissues resembling the stable osteochondral
unit of joints. When developmentally inspired differen-
tiation conditions were applied, hPDCs generated
bilayered constructs displaying osteochondral potential.
At the molecular level, these constructs expressed genes
associated with stable articular chondrocytes, such as
SOX9, COL2A1, and NOGGIN, along with the hyper-
trophic genes MEF2C and COL10A1. Higher expression
of NOGGIN in TIs as compared to hACs suggests the
presence of endogenous mechanisms to control BMP
signaling and avoid the potential hypertrophic differenti-
ation effect of BMP signaling in TIs. Indeed, a significant
lower expression of GREMLIN1 in TIs as compared
with hACs suggests that NOGGIN is potentially the
main regulator of the BMP pathway in this system. Sur-
prisingly, control aggregates displayed an increased ex-
pression of PRG4, which raises the question of whether
expanded hPDCs encompass a subpopulation of PRG4+
cells that can be maintained under specific culture con-
ditions. Since PRG4 has recently been suggested as a
potential marker of joint interzone progenitor cells [39],
this observation might be of particular interest in the
field of cartilage tissue engineering.
At the histological level, a time-dependent increase in
IHH expression, cartilage ECM deposition (GAGs and
type-II collagen), and establishment of different bio-
logical gradients from the top to the bottom cell layers
of the TIs were found. This hierarchical organization of
hPDC-derived chondrocytes, ranging from a dual type-
II/type-I collagen-expressing zone to a type-I collagen-
expressing zone, suggested an in vitro recapitulation of
some aspects of the osteochondral differentiation. Based
on previous studies, we hypothesized that different gra-
dients of oxygen, nutrients, and GFs through the con-
structs and/or the contact with the plastic surface of the
culture vessel might contribute to this self-patterning
event [40–43]. Whilst it is unclear which of the constitu-
ents of the bi-layered construct are important for osteo-
chondral repair, we believe the advantages are clear from
the impressive tissue regeneration observed compared
with other treatments.
It is noteworthy that ectopic implantation of TIs in
nude mice showed either the generation of ossicles or
“stable” mineralized cartilage. Considering that MSC-
derived chondrocytes are permissive to cartilage remod-
eling and bone formation via endochondral ossification
[44, 45], our findings may represent a significant advance
towards the generation of articular cartilage tissue-
engineered constructs. Also, both donor and host cells
contributed to in vivo tissue formation, as showed by
anti-human osteocalcin. Osteocalcin-positive cells are
likely to contribute to the mineralization events within
the cartilage matrix, as this protein acts as a nucleation
site for hydroxyapatite deposition [46]. Osteocalcin ex-
pression can potentially be explained by the in vitro acti-
vation of the BMP pathway, which is known to
contribute to cartilage mineralization [47]. Interestingly,
the mineralized cartilage displayed type-II collagen de-
position and seemed to be protected from vascular inva-
sion and matrix remodeling, which suggested that the
TIs were stabilized at a prehypertrophic chondrogenic
state. Moreover, ectopic maintenance of structural type-
II to type-I collagen gradients suggested an intrinsic
capacity of the TIs to commit to an osteochondral differ-
entiation process similar to that of the osteochondral
unit. To test this hypothesis, a critical-size osteochondral
defect model was used. To investigate the contribution
of the orthotopic microenvironment and to separate that
from the contribution of the chondrogenic medium
used, cell aggregates cultured in basal chondrogenic
medium supplement with 10 ng/ml TGF-β1 were also
tested. TGF-β1 was chosen because of its known poten-
tial to induce chondrogenic differentiation of hPDCs
[25]. Following 8 weeks of implantation in osteochondral
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defects, μCT analysis showed significant differences at
the level of subchondral bone regeneration between con-
ditions, especially in osteochondral defects treated with
TGF-β1 aggregates where limited subchondral bone re-
generation was observed. This correlated with an accu-
mulation of fibrocartilage tissue in the subchondral bone
area. Gene expression analysis prior to implantation in-
dicated that chondrocyte differentiation through TGF-β1
triggers not only a significant increase in COL2A1 and
COL10A1, but also a fibrotic tissue response involving
Plod2, COL5A1, and COL1A1 [29–32]. These data cor-
roborate previous studies that correlated the overexpres-
sion of TGF-β signaling with cartilage degradation in
murine OA models [48, 49]. Nevertheless, TGF-β1 ag-
gregates were able to express lubricin at the joint surface
8 weeks postinjury, possibly as a direct effect of TGF-β1
stimulation in superficial articular chondrocytes [50].
Defects treated with TIs displayed subchondral bone re-
generation to levels similar to normal knees and empty
defects, with human cells contributing to this process.
At the joint surface, these defects displayed increased
GAG, type-II collagen, and lubricin deposition, notably
with human cells also contributing to these processes.
These data indicate that periosteal cell expansion and dif-
ferentiation under optimized conditions can generate an
enhanced outcome when compared to autologous osteo-
periosteal transplantation into osteochondral defects. In-
deed, while osteoperiosteal transplantation improves
osseointegration, concurrent deterioration of the overlying
cartilage repair tissue is observed [51].
Despite the encouraging results provided herein,
long-term follow-up is necessary to characterize the
stability of the new cartilage-subchondral bone unit
which was formed. Despite this, it is hypothesized that
the regeneration of the subchondral bone is likely to
contribute to the stability of the newly formed cartilage
layer, as early subchondral bone loss is thought to con-
tribute to OA initiation.
Conclusions
In summary, we report the potency of a novel GF cocktail
for osteochondral differentiation of expanded hPDCs. This
GF cocktail allows either progression or stabilization of
the cartilage phenotype in a microenvironment-dependent
manner, supporting the hypothesis that a scaffold-free
tissue-engineered construct from hPDCs can be engi-
neered in vitro for treatment of osteochondral defects.
This apparent plasticity allows the osteochondral-like im-
plants described herein to have applications in treating
focal chondral lesions and full thickness osteochondral
defects, thus potentially reducing the incidence of OA
from the current estimate of 15% of all adults aged over
60 years.
Additional files
Additional file 1: Table S1. Details of the antibodies and
immunohistochemistry protocols employed. (DOCX 17 kb)
Additional file 2: Figure S1. Early mineralization patterns of TIs at 2
weeks after ectopic implantation in nude mice. Left: alcian blue staining
showing the presence of mineralized cartilage in the top layers of the
construct (encircled by dotted black lines) and vascular ingrowth from
the bottom layers (black arrows). Right: μCT cross-section confirming
the presence of mineralized tissues (encircled by dotted black lines)
and nonmineralized GAG-positive tissues, between white and black
lines (Visualization of nonmineralized cartilage was possible following
incubation with Hexabrix, a cartilage contrast agent). (TIFF 14998 kb)
Additional file 3: Figure S2. Gene expression analysis of chondrogenesis
in CTRL, TIs, TGF-β1 aggregates, and hACs after 28 days in culture. Results
are representative of two independent experiments, each experiment
was performed in triplicate. error bars are max/min; *P < 0.05, **P < 0.01,
***P < 0.001. (TIFF 240 kb)
Abbreviations
ACI: Autologous chondrocyte implantation; BCM: Basal chondrogenic
medium; BMP: Bone morphogenetic protein; BSA: Bovine serum albumin;
CTRL: Control; DMEM: Dulbecco’s modified Eagle’s medium;
ECM: Extracellular matrix; FBS: Fetal bovine serum; FGF: Fibroblast growth
factor; GAG: Glycosaminoglycan; GDF: Growth differentiation factor;
GF: Growth factor; H&E: Hematoxylin and eosin; H2O2: Hydrogen peroxide;
hACs: Human articular chondrocytes; hPDC: Human periosteum-derived pro-
genitor cell; HRP: Horseradish peroxidase; IHH: Indian Hedgehog;
MSC: Mesenchymal stem cell; OA: Osteoarthritis; PBS: Phosphate-buffered
saline; PFA: Paraformaldehyde; qRT-PCR: Quantitative reverse transcription
polymerase chain reaction; ROI: Region of interest; TBST: Tris-buffered saline
and 0.1% Tween 20; TGF: Transforming growth factor; TI: Tissue intermediate;
μCT: Microcomputed tomography
Acknowledgements
This work is part of Prometheus, the KU Leuven R&D division for skeletal tissue
engineering (http://www.kuleuven.be/prometheus). The research leading to
these results has received funding from the European Research Council under
the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC
Grant Agreements nos. 279100 and 294191; from the special research fund of
the KU Leuven (GOA/13/016) and the Stem Cell Institute of Leuven–KU Leuven.
Funding
This work is part of Prometheus, the KU Leuven R&D division for skeletal
tissue engineering. http://www.kuleuven.be/prometheus. The research
leading to these results has received funding from the European Research
Council under the European Union’s Seventh Framework Programme (FP/
2007-2013)/ERC Grant Agreements n. 279100 and 294191; from the Research
Programme of the Research Foundation – Flanders (FWO), grant no.
1.5.172.13 N-Interdisc, and from the special research fund of the KU Leuven
(GOA/13/016).
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
LFM conceived the study, performed all experiments, and participated in its
design. HK participated in the design and performed analysis. WLT participated
in the design and performed analysis. YCC participated in the design and
performed analysis. LG participated in the design and performed analysis. SJR
conceived the study and participated in its design. FPL conceived the study and
participated in its design. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The ethical committee for Human Medical Research (KU Leuven) approved
all procedures, and patient informed consent forms were obtained. All
animal experimental procedures were approved by the local ethical
committee for animal research (KULeuven). The animals were housed
according to the guidelines provided by the Animalium Leuven (KULeuven).
Mendes et al. Stem Cell Research & Therapy  (2018) 9:42 Page 11 of 13
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Tissue Engineering Laboratory, Skeletal Biology and Engineering Research
Center, KU Leuven, Campus Gasthuisberg O&N 1, Herestraat 49, bus 813,
3000 Leuven, Belgium. 2Prometheus, Division of Skeletal Tissue Engineering,
KU Leuven, O&N 1, Herestraat 49, bus 813, 3000 Leuven, Belgium.
3Biomechanics Research Unit, University of Liege, Chemin des Chevreuils 1 –
BAT 52/3, 4000 Liege 1, Belgium. 4Biomechanics Section, KU Leuven,
Celestijnenlaan 300C bus 2419, 3001 Leuven, Belgium. 5Institute of
Orthopaedics and Musculoskeletal Science, Division of Surgery &
Interventional Science, University College London, The Royal National
Orthopaedic Hospital, Stanmore, Middlesex HA7 4LP, UK.
Received: 22 October 2017 Revised: 4 January 2018
Accepted: 22 January 2018
References
1. Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage
injuries: a review of 31,516 knee arthroscopies. Arthroscopy. 1997;13:456–60.
2. Widuchowski W, Widuchowski J, Trzaska T. Articular cartilage defects: study
of 25,124 knee arthroscopies. Knee. 2007;14:177–82.
3. Gelber AC, Hochberg MC, Mead LA, Wang N, Wigley FM, Klag MJ. Joint
injury in young adults and risk for subsequent knee and hip osteoarthritis.
Ann Intern Med. 2000;133:321–8.
4. Davis MA, Ettinger WH, Neuhaus JM, Cho SA, Hauck WW. The association of
knee injury and obesity with unilateral and bilateral osteoarthritis of the
knee. Am J Epidemiol. 1989;130:278–88.
5. Cooper C, Inskip H, Croft P, Campbell L, Smith G, McLaren M, Coggon D.
Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical
activity. Am J Epidemiol. 1998;147:516–22.
6. Brown TD, Johnston RC, Saltzman CL, Marsh JL, Buckwalter JA.
Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and
burden of disease. J Orthop Trauma. 2006;20:739–44.
7. Salzmann GM, Sah B, Sudkamp NP, Niemeyer P. Reoperative characteristics
after microfracture of knee cartilage lesions in 454 patients. Knee Surg
Sports Traumatol Arthrosc. 2013;21:365–71.
8. Sherman SL, Garrity J, Bauer K, Cook J, Stannard J, Bugbee W. Fresh
osteochondral allograft transplantation for the knee: current concepts. J Am
Acad Orthop Surg. 2014;22:121–33.
9. Farr J, Gracitelli GC, Shah N, Chang EY, Gomoll AH. High failure rate of a
decellularized osteochondral allograft for the treatment of cartilage lesions.
Am J Sports Med. 2016;44(8):2015–22.
10. Huang BJ, Hu JC, Athanasiou KA. Cell-based tissue engineering strategies
used in the clinical repair of articular cartilage. Biomaterials. 2016;98:1–22.
11. Niemeyer P, Salzmann G, Steinwachs M, Sudkamp NP, Schmal H, Lenz P, Kostler
W. Presence of subchondral bone marrow edema at the time of treatment
represents a negative prognostic factor for early outcome after autologous
chondrocyte implantation. Arch Orthop Trauma Surg. 2010;130:977–83.
12. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S.
Autologous bone marrow stromal cell transplantation for repair of full-
thickness articular cartilage defects in human patellae: two case reports. Cell
Transplant. 2004;13:595–600.
13. Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, Ohgushi H,
Wakitani S, Kurosaka M. Treatment of a full-thickness articular cartilage
defect in the femoral condyle of an athlete with autologous bone-marrow
stromal cells. Osteoarthr Cartil. 2007;15:226–31.
14. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of
articular cartilage defects in the patello-femoral joint with autologous bone
marrow mesenchymal cell transplantation: three case reports involving nine
defects in five knees. J Tissue Eng Regen Med. 2007;1:74–9.
15. Narcisi R, Cleary MA, Brama PA, Hoogduijn MJ, Tüysüz N, ten Berge D, van
Osch GJ. Long-term expansion, enhanced chondrogenic potential, and
suppression of endochondral ossification of adult human MSCs via WNT
signaling modulation. Stem Cell Rep. 2015;4(3):459–72.
16. Murphy MK, Huey DJ, Hu JC, Athanasiou KA. TGF-β1, GDF-5, and BMP-2
stimulation induces chondrogenesis in expanded human articular
chondrocytes and marrow-derived stromal cells. Stem Cells. 2015;33:762–73.
17. Lolli A, Narcisi R, Lambertini E, Penolazzi L, Angelozzi M, Kops N, Gasparini S,
van Osch GJ, Piva R. Silencing of antichondrogenic microRNA-221 in human
mesenchymal stem cells promotes cartilage repair in vivo. Stem Cells.
2016;34:1801–11.
18. Ng JJ, Wei Y, Zhou B, Bernhard J, Robinson S, Burapachaisri A, Guo XE,
Vunjak-Novakovic G. Recapitulation of physiological spatiotemporal signals
promotes in vitro formation of phenotypically stable human articular
cartilage. Proc Natl Acad Sci. 2017;114:2556–61.
19. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L.
Treatment of deep cartilage defects in the knee with autologous
chondrocyte transplantation. N Engl J Med. 1994;331:889–95.
20. O’Driscoll SW, Fitzsimmons JS. The role of periosteum in cartilage repair.
Clin Orthop Relat Res. 2001;391:S190–207.
21. Korkala O, Kuokkanen H. Autogenous osteoperiosteal grafts in the
reconstruction of full-thickness joint surface defects. Int Orthop. 1991;15:233–7.
22. Scotti C, Gobbi A, Karnatzikos G, Martin I, Shimomura K, Lane JG, Peretti GM,
Nakamura N. Cartilage repair in the inflamed joint: considerations for biological
augmentation towards tissue regeneration. Tissue Eng Part B Rev. 2015;22:149–59.
23. Mendes LF, Tam WL, Chai YC, Geris L, Luyten FP, Roberts SJ. Combinatorial
analysis of growth factors reveals the contribution of bone morphogenetic
proteins to chondrogenic differentiation of human periosteal cells. Tissue
Eng Part C Methods. 2016;22:473–86.
24. Eyckmans J, Roberts SJ, Schrooten J, Luyten FP. A clinically relevant model
of osteoinduction: a process requiring calcium phosphate and BMP/Wnt
signalling. J Cell Mol Med. 2010;14:1845–56.
25. De Bari C, Dell’Accio F, Luyten FP. Human periosteum-derived cells maintain
phenotypic stability and chondrogenic potential throughout expansion
regardless of donor age. Arthritis Rheum. 2001;44:85–95.
26. Lee S, Kim JH, Jo CH, Seong SC, Lee JC, Lee MC. Effect of serum and growth
factors on chondrogenic differentiation of synovium-derived stromal cells.
Tissue Eng Part A. 2009;15:3401–15.
27. Eyckmans J, Lin GL, Chen CS. Adhesive and mechanical regulation of
mesenchymal stem cell differentiation in human bone marrow and
periosteum-derived progenitor cells. Biol Open. 2012;1(11):1058–68.
28. Roberts SJ, Geris L, Kerckhofs G, Desmet E, Schrooten J, Luyten FP. The
combined bone forming capacity of human periosteal derived cells and
calcium phosphates. Biomaterials. 2011;32:4393–405.
29. Wu L, Petrigliano FA, Ba K, Lee S, Bogdanov J, McAllister DR, Adams JS,
Rosenthal AK, Van Handel B, Crooks GM, et al. Lysophosphatidic acid
mediates fibrosis in injured joints by regulating collagen type I biosynthesis.
Osteoarthr Cart. 2015;23:308–18.
30. Remst DFG, Blaney Davidson EN, Vitters EL, Blom AB, Stoop R, Snabel JM,
Bank RA, van den Berg WB, van der Kraan PM. Osteoarthritis-related fibrosis
is associated with both elevated pyridinoline cross-link formation and lysyl
hydroxylase 2b expression. Osteoarthr Cartil. 2013;21:157–64.
31. Pfander D, Heinz N, Rothe P, Carl HD, Swoboda B. Tenascin and aggrecan
expression by articular chondrocytes is influenced by interleukin 1beta: a
possible explanation for the changes in matrix synthesis during
osteoarthritis. Ann Rheum Dis. 2004;63:240–4.
32. Mak KM, Png CY, Lee DJ. Type V collagen in health, disease, and fibrosis.
Anat Rec (Hoboken). 2016;299:613–29.
33. Freyria A-M, Mallein-Gerin F. Chondrocytes or adult stem cells for cartilage
repair: the indisputable role of growth factors. Injury. 2012;43:259–65.
34. Hillel AT, Taube JM, Cornish TC, Sharma B, Halushka M, McCarthy EF,
Hutchins GM, Elisseeff JH. Characterization of human mesenchymal stem
cell-engineered cartilage: analysis of its ultrastructure, cell density and
chondrocyte phenotype compared to native adult and fetal cartilage. Cells
Tissues Organs. 2010;191:12–20.
35. Mauck RL, Yuan X, Tuan RS. Chondrogenic differentiation and functional
maturation of bovine mesenchymal stem cells in long-term agarose culture.
Osteoarthr Cart. 2006;14:179–89.
36. Steck E, Bertram H, Abel R, Chen B, Winter A, Richter W. Induction of
intervertebral disc-like cells from adult mesenchymal stem cells. Stem Cells.
2005;23:403–11.
37. Ando W, Tateishi K, Hart DA, Katakai D, Tanaka Y, Nakata K, Hashimoto J,
Fujie H, Shino K, Yoshikawa H, Nakamura N. Cartilage repair using an in vitro
Mendes et al. Stem Cell Research & Therapy  (2018) 9:42 Page 12 of 13
generated scaffold-free tissue-engineered construct derived from porcine
synovial mesenchymal stem cells. Biomaterials. 2007;28:5462–70.
38. Koizumi K, Ebina K, Hart DA, Hirao M, Noguchi T, Sugita N, Yasui Y, Chijimatsu
R, Yoshikawa H, Nakamura N. Synovial mesenchymal stem cells from osteo- or
rheumatoid arthritis joints exhibit good potential for cartilage repair using a
scaffold-free tissue engineering approach. Osteoarthr Cart. 2016;24:1413–22.
39. Kozhemyakina E, Zhang M, Ionescu A, Ayturk UM, Ono N, Kobayashi A,
Kronenberg H, Warman ML, Lassar AB. Identification of a Prg4-expressing
articular cartilage progenitor cell population in mice. Arthritis Rheumatol.
2015;67:1261–73.
40. Malda J, Rouwkema J, Martens DE, le Comte EP, Kooy FK, Tramper J, van
Blitterswijk CA, Riesle J. Oxygen gradients in tissue-engineered Pegt/Pbt
cartilaginous constructs: Measurement and modeling. Biotechnol Bioeng.
2004;86:9–18.
41. Zhou S, Cui Z, JPG U. Nutrient gradients in engineered cartilage: metabolic
kinetics measurement and mass transfer modeling. Biotechnol Bioeng.
2008;101:408–21.
42. Bursac PM, Freed LE, Biron RJ, Vunjak-Novakovic G. Mass transfer studies of
tissue engineered cartilage. Tissue Eng. 1996;2:141–50.
43. Rohner D, Hutmacher DW, Cheng TK, Oberholzer M, Hammer B. In vivo
efficacy of bone-marrow-coated polycaprolactone scaffolds for the
reconstruction of orbital defects in the pig. J Biomed Mater Res B Appl
Biomater. 2003;66:574–80.
44. Farrell E, Both SK, Odorfer KI, Koevoet W, Kops N, O’Brien FJ, de Jong RJB,
Verhaar JA, Cuijpers V, Jansen J, et al. In-vivo generation of bone via
endochondral ossification by in-vitro chondrogenic priming of adult human
and rat mesenchymal stem cells. BMC Musculoskelet Disord. 2011;12:31.
45. Scotti C, Tonnarelli B, Papadimitropoulos A, Scherberich A, Schaeren S,
Schauerte A, Lopez-Rios J, Zeller R, Barbero A, Martin I. Recapitulation of
endochondral bone formation using human adult mesenchymal stem cells
as a paradigm for developmental engineering. Proc Natl Acad Sci.
2010;107:7251–6.
46. Lian JB, McKee MD, Todd AM, Gerstenfeld LC. Induction of bone-related
proteins, osteocalcin and osteopontin, and their matrix ultrastructural
localization with development of chondrocyte hypertrophy in vitro. J Cell
Biochem. 1993;52:206–19.
47. Hellingman CA, Davidson EN, Koevoet W, Vitters EL, van den Berg WB, van
Osch GJ, van der Kraan PM. Smad signaling determines chondrogenic
differentiation of bone-marrow-derived mesenchymal stem cells: inhibition
of Smad1/5/8P prevents terminal differentiation and calcification. Tissue Eng
Part A. 2011;17:1157–67.
48. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB.
Osteoarthritis-like changes in the murine knee joint resulting from intra-
articular transforming growth factor-beta injections. Osteoarthr Cart.
2000;8:25–33.
49. Shen J, Li S, Chen D. TGF-β signaling and the development of osteoarthritis.
Bone Res. 2014;2:14002.
50. Cuellar A, Reddi AH. Stimulation of superficial zone protein/lubricin/PRG4 by
transforming growth factor-beta in superficial zone articular chondrocytes
and modulation by glycosaminoglycans. Tissue Eng Part A. 2015;21:1973–81.
51. Gotterbarm T, Breusch SJ, Vilei SB, Mainil-Varlet P, Richter W, Jung M. No
effect of subperiosteal growth factor application on periosteal neo-
chondrogenesis in osteoperiosteal bone grafts for osteochondral defect
repair. Int Orthop. 2013;37:1171–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mendes et al. Stem Cell Research & Therapy  (2018) 9:42 Page 13 of 13
